- Home
- VYGR vs LDI Comparison
VYGR vs LDI Comparison
Compare VYGR & LDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- LDI
- Stock Information
- Founded
- VYGR 2013
- LDI 2010
- Country
- VYGR United States
- LDI United States
- Employees
- VYGR N/A
- LDI N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- LDI Finance: Consumer Services
- Sector
- VYGR Health Care
- LDI Finance
- Exchange
- VYGR Nasdaq
- LDI Nasdaq
- Market Cap
- VYGR 342.5M
- LDI 410.7M
- IPO Year
- VYGR 2015
- LDI 2021
- Fundamental
- Price
- VYGR $5.75
- LDI $1.94
- Analyst Decision
- VYGR Strong Buy
- LDI Sell
- Analyst Count
- VYGR 9
- LDI 3
- Target Price
- VYGR $16.44
- LDI $2.60
- AVG Volume (30 Days)
- VYGR 485.6K
- LDI 838.0K
- Earning Date
- VYGR 11-12-2024
- LDI 11-05-2024
- Dividend Yield
- VYGR N/A
- LDI N/A
- EPS Growth
- VYGR N/A
- LDI N/A
- EPS
- VYGR 0.47
- LDI N/A
- Revenue
- VYGR $163,784,000.00
- LDI $1,013,388,000.00
- Revenue This Year
- VYGR N/A
- LDI N/A
- Revenue Next Year
- VYGR N/A
- LDI $24.10
- P/E Ratio
- VYGR $12.33
- LDI N/A
- Revenue Growth
- VYGR 3.40
- LDI 10.36
- 52 Week Low
- VYGR $5.19
- LDI $1.52
- 52 Week High
- VYGR $11.72
- LDI $3.71
- Technical
- Relative Strength Index (RSI)
- VYGR 41.30
- LDI 35.22
- Support Level
- VYGR $6.08
- LDI $1.83
- Resistance Level
- VYGR $6.55
- LDI $2.24
- Average True Range (ATR)
- VYGR 0.35
- LDI 0.12
- MACD
- VYGR -0.05
- LDI -0.03
- Stochastic Oscillator
- VYGR 14.51
- LDI 19.44
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.